RAD52 and ovarian cancer: Additionally, a recent work reported, for example, that the S346X mutation in RAD52 was found to correlate with a significant reduction in breast and ovarian cancer risk for germline BRCA2 mutation carriers, supporting the idea that RAD52 defects in BRCA-mutated carriers could lead to a lower risk of tumor development [87].